ABL signs international distribution agreement for Virco BVBA's HIV resistance interpretation system

Jul 13 2010

Advanced Biological Laboratories (ABL) is pleased to announce its recent signature of a non-exclusive international distribution agreement (excluding United States, Australia, Canada and United Kingdom) of virco^®TYPE HIV-1, Belgium-based Virco BVBA's HIV resistance interpretation system.

ABL will offer virco^®TYPE HIV-1 through its electronic medical record and decision support system TherapyEdge™ HIV. virco^®TYPE HIV-1 results (raw data and report) will be available together with full patient's details and will support the healthcare providers' virological and clinical decisions taking care of HIV-infected patients experiencing virological failure and HIV drug resistance.

The distribution of virco^®TYPE HIV-1 will complete ABL's portfolio of online services in electronically based bioinformatics tools currently provided through its TherapyEdge™ and ViroScore™ Suite platform.

ABL distributes several proprietary systems developed by international experts companies and research teams, including the COMET® software (virus subtype characterization, licensed from the CRP-Santé (www.crp-sante.lu), in Luxembourg, the FibroMeter™ viral Hepatitis online interpretation system (liver fibrosis scoring from BioLiveScale (www.biolivescale.com), in France) and the SeqHepB® online interpretation system (HBV drug resistance interpretation system from Evivar Medical (www.evivar.com), in Australia).

The ViroScore™ Suite platform includes also several genotypic HIV drug resistance interpretation algorithms developed and validated by several worldwide HIV/AIDS experts from medical hospitals and universities in the USA, in Belgium, in France, in Spain, in Luxembourg and in Brazil.

SOURCE Advanced Biological Laboratories (ABL) S.A.